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Abstract 
Objective: Paragonimiasis is a foodborne trematode infection of the lungs caused by Paragonimus spp., presenting 
clinically with similar symptoms to active tuberculosis (TB). Worldwide, an estimated 20.7 million people are infected 
with paragonimiasis, but relatively little epidemiological data exists for Africa. Given a recently reported case, we 
sought to establish whether paragonimiasis should be considered as an important differential diagnosis for human TB 
in The Gambia, West Africa.
Results: We developed a novel PCR-based diagnostic test for Paragonimus species known to be found in West Africa, 
which we used to examine archived TB negative sputum samples from a cross-sectional study of volunteers with 
tuberculosis-like symptoms from communities in the Western coastal region of The Gambia. Based on a “zero patient” 
design for detection of rare diseases, 300 anonymised AFB smear negative sputum samples, randomly selected from 
25 villages, were screened for active paragonimiasis by molecular detection of Paragonimus spp. DNA. No parasite 
DNA was found in any of the sputa of our patient group. Despite the recent case report, we found no evidence of 
active paragonimiasis infection masking as TB in the Western region of The Gambia.
Keywords: Paragonimiasis, Paragonimus, West Africa, Foodborne trematodiases, Neglected tropical diseases, 
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Introduction
Tuberculosis (TB) is a major global public health con-
cern. The mainstay of TB diagnosis, particularly in devel-
oping countries, is sputum smear-microscopy [1]. As a 
result, verifying differential diagnosis for persons with 
clinical symptoms and a smear-negative microscopy 
result is difficult. Besides smear negative, culture positive 
TB, common alternative diagnoses include non-tubercu-
lous mycobacteria and in some parts of the world, para-
gonimiasis, a food-borne trematode infection caused by 
the Paragonimus spp. [2].
Paragonimus is a highly neglected and poorly known 
infection acquired through ingestion of undercooked 
crustacea [3, 4], which infects a range of mammals 
including humans, where symptoms are synonymous 
with TB infection [5, 6]. Diagnostic confusion between 
TB and paragonimiasis is common in countries such 
as India [6] and The Philippines [7], and has resulted in 
investment in training and integrated diagnostic proce-
dures for all TB suspects in some areas. In West Africa, 
epidemiological data describing the burden of para-
gonimiasis is scarce, with studies limited to Nigeria and 
Cameroon [8, 9]. Though case reports from Liberia, 
Benin and Cote d’Ivoire have also been documented [10–
12]. Whilst the species Paragonimus westermani and P. 
heterotremus are the most common species worldwide, in 
Africa only P. africanus and P. uterobilateralis have been 
found thus far [12, 13].
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In The Gambia, West Africa, there is anecdotal evi-
dence of Paragonimus infection and crustaceans are 
included in the local diet, although there is little doc-
umented evidence of culinary practices that might 
increase risk of consuming undercooked crabs. As 
recently as 2011, there was a confirmed case in a 12 year 
old Gambian boy returning from Casamance, the Sen-
egalese region immediately south of our study area, who 
was infected with Paragonimus after reportedly consum-
ing raw crabmeat (Richard Bradbury, personal communi-
cation). In addition, four case reports were described in 
patients originating from Casamance in the 1960s [12, 
14]. Therefore, one possible alternative diagnosis for indi-
viduals who are smear-negative with TB-like symptoms 
in The Gambia could be paragonimiasis.
Nested into a cluster-randomised TB enhanced case 
finding (ECF) study conducted in The Gambia from 
December 2011 to November 2014, we carried out the 
first epidemiological study of paragonimiasis amongst 
smear-negative Gambian TB suspects living in the 
coastal region bordering Casamance. Using archived spu-
tum samples from the ECF study, our aim was to conduct 
a rapid appraisal of whether human paragonimiasis was 
an important differential diagnosis for TB in this region 
of the Gambia, which might warrant more extensive sur-
veys and investment in training, awareness and diagnos-
tic facilities for this neglected parasite. We further aimed 
to develop a diagnostic test for paragonimiasis suitable 
for surveys in West Africa.
Main text
Materials and methods
Study area
For the TB-ECF study, field teams sensitised commu-
nity members in villages through video presentations in 
local languages explaining TB symptoms, diagnosis and 
treatment. All villages were located in the coastal Greater 
Banjul area of The Gambia and the area bordering Casa-
mance in southern Senegal. Patients with self-reported 
coughing and production of two sputum samples were 
enrolled regardless of age and gender. Written informed 
consent was provided by all participants including writ-
ten parental consent for minors and assent where appro-
priate. No additional exclusion criteria applied to those 
meeting the criteria for inclusion. For the paragonimus 
study, a subset of 300 archived patient sputa negative on 
two Acid-fast Bacteria (AFB) smears were tested for the 
presence of Paragonimus DNA, therefore the investiga-
tors were not blinded to AFB-smear status. AFB smear 
microscopy was performed on fresh samples received 
directly from the field before sample archiving. Sample 
size calculation for this study was based on the “zero 
prevalence” model for detection of rare diseases [15]. 
This model calculates that an absence of cases found 
in 300 samples would mean it could be stated with 
95% confidence that prevalence of an infection is  <  1% 
amongst the study population of smear-negative TB sus-
pects. In order to maximise geographic coverage, twelve 
anonymised AFB-smear negative sputum samples origi-
nating from each of 25 villages in the ECF study were 
randomly selected for analysis.
Sputum sample processing and DNA extraction
An equivolume of mucolysis solution (0.5% N-acetyl 
l-cysteine, 2% sodium hydroxide, 1.45% tri-sodium cit-
rate) was added to 1.5 ml of stored sputa, vortexed and 
incubated at room temperature. After 15 min, each sam-
ple was made up to a volume of 50  ml with phosphate 
buffered saline (PBS) and centrifuged at 3000  rpm for 
20 min. The pellet was re-suspended in 200 µl PBS and 
heat inactivated at 99 °C for 20 min.
DNA was purified from 200  µl of each sample using 
QIAamp DNA mini kit spin columns (Qiagen Ltd., 
Hilden, Germany, Ref. 51306) following the standard 
manufacturer’s protocol for extraction from body fluids. 
The DNA was eluted in a final volume of 150 µl elution 
buffer and stored at − 20 °C.
Successful DNA extraction was monitored by real-time 
amplification of the human ribonuclease P gene (RNaseP) 
as an internal positive control. Reagents were prepared 
in 25  µl final volume to the following concentrations: 
1 ×  Platinum® Quantitative PCR SuperMix-UDG (Inv-
itrogen, Massachusetts, USA, Ref 1173-025), 0.2 pmol of 
each primer; RNaseP-F and RNaseP-B, 0.2  pmol probe 
RNaseP-P, 3.0 mM  MgCl2, 0.1x ROX reference dye (Invit-
rogen, Ref. 12223-012) and 2.5 µl template DNA. Primer 
and probe sequences are found in Additional file 1: Table 
S1. In an ABI7500 real-time PCR system (Applied Biosys-
tems, Massachusetts, USA), samples were amplified with 
the following cycling parameters: 1 cycle at 50 °C/2 min, 1 
cycle at 95 °C/10 min, followed by 45 cycles of 95 °C/15 s 
and 60 °C/1 min.
Paragonimus spp. PCR assay development
The internal transcribed spacer 2 (ITS-2) region of Para-
gonimus spp. was chosen as the target region for the PCR 
assay. Sequences were obtained from GenBank for P. afri-
canus (accession no. AB298780) and kindly provided by 
Professor David Blair (James Cook University, Australia) 
for P. uterobilateralis (unpublished data). The assay used 
was modified from a PCR-based assay published by Chen 
et al. (2011). This assay was designed to target the ITS-2 
sequence of P. westermani (primers PW-F and PW-B), for 
our study of paragonimiasis in The Gambia, however, the 
reverse primer was redesigned for greater specificity to 
the endemic species; P. africanus and P. uterobilateralis 
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(PAU-B) (for primer sequences see Additional file  1: 
Table S1).
Due to the highly neglected status of paragonimiasis 
in West Africa, no P. africanus or P. uterobilateralis con-
trol worms were available despite efforts to source them. 
Thus positive control plasmids encoding ITS-2 were 
synthesised for both P. africanus and P. uterobilateralis 
(Eurofins Genomics, Ebersberg, Germany) and ampli-
fied in the following PCR conditions: 1U Taq PCR Mas-
ter Mix Kit (Qiagen Ltd., Hilden, Germany, Ref. 201445), 
10  pmol of each forward (PW-F) and reverse primer 
(PW-B or PAU-B), 1  µl template DNA and 9.5  µl PCR-
grade  H2O in a final reaction volume of 25 µl. PCR con-
ditions included an initial denaturation at 94  °C/5  min, 
35 cycles 94 °C/30 s (denaturation), 55 °C/1 min (anneal-
ing) and at 72  °C/30  s (extension) and a final extension 
at 72 °C/5 min. The expected PCR product size was 221 
base pairs (bp).
Results
Study population
Descriptive patient characteristics of 300 smear-negative 
patients from an enhanced case-finding study for TB in 
the Greater Banjul region of The Gambia whose sputum 
samples were randomly selected for inclusion in this 
study are shown in Table 1.
Paragonimus spp. PCR assay validation
The modified assay’s (PW-F/PAU-B) detection limit was 
estimated using a dilution series of the plasmid positive 
control DNA. Dilutions of the P. africanus and P. uterobi-
lateralis positive controls were prepared to the following 
concentrations: 1000, 100, 10, 5, 1, 0.5, 0.1 pg/µl. 1 µl of 
each was used as template DNA per reaction using prim-
ers PW-F/PAU-B. Overall the PCR assay demonstrated 
sensitivity at levels lower than 0.1 pg/µl when pure posi-
tive control alone was used as template DNA (Fig.  1a). 
The same dilution series of positive control DNA was 
then used to spike 200 µl decontaminated sputum sedi-
ment. Extracted sputum samples, spiked with plasmid 
positive control displayed sensitivity levels of 5 and 
100 pg/µl of DNA for P. africanus and P. uterobilateralis, 
respectively (Fig. 1b). The sensitivity of the PW-F/PAU-B 
assay was also shown to be greater for the two West Afri-
can target species, P. africanus and P. uterobilateralis, 
compared to P. westermani (Fig. 1c).
Primer specificity was validated by assaying known 
positive DNA of helminth species closely related to Para-
gonimus spp. using both PW-F/PW-B and our adapted 
PW-F/PAU-B primer combinations (Fig.  1d). The Para-
gonimus spp. samples produced a band of 221  bp as 
expected. No amplification was detected with either 
primer pair and S. mansoni, S. haematobium or N. ameri-
canus DNA. There was no amplification product using 
Opisthorchis DNA and the primer combination PW-F/
PW-B. Amplifying Opisthorchis DNA using our modified 
primers PW-F/PAU-B resulted in a substantially larger 
band (800 bp), clearly distinguishable from Paragonimus 
bands (221 bp).
PCR analysis of clinical samples
The quality of the DNA extractions was verified in 10% 
(n  =  30) of samples, selected at random. All samples 
were positive for RNaseP, suggesting DNA was success-
fully extracted from sputa (data not shown). We selected 
the PW-F/PAU-B combination for analysis of the clini-
cal samples. All TB smear-negative sputum samples 
(n = 300) were tested. 10.7% (n = 32/300) samples ampli-
fied a band larger than the expected product size, approxi-
mately 250 bp. Twenty of these potentially positives were 
validated by DNA sequencing (Macrogen, Amsterdam, 
The Netherlands), analysed using Geneous V.7.1 sequence 
alignment and editing software (Biomatters, Auckland, 
New Zealand) and it was confirmed none of these ampli-
cons were Paragonimus spp. sequences through BLAST 
searches against the GenBank (NCBI, MD, USA) data-
base. These results indicate that no Paragonimus infection 
was detected in the sputa examined in this study. Based 
on the zero prevalence model, a case detection rate of 
zero was interpreted (with 95% confidence) as a preva-
lence less than 1% in our study population.
Discussion
Paragonimiasis is a neglected yet emerging global health 
problem. It is especially important as differential diagno-
sis of TB [6, 16] and its potential large cost implications 
of mis-diagnosis for TB control programs. Although 
previous reports suggest that the disease is present in 
the Senegambian region we did not detect any cases of 
Paragonimus DNA in samples from symptomatic but 
TB-smear negative patients. The sample size was based 
Table 1 Descriptive patient characteristics
N (%)
Gender
 Female 171 (57)
 Male 129 (43)
Age
 < 10 9 (3)
 10–25 57 (19)
 26–40 75 (25)
 41–55 89 (29.7)
 56–70 47 (15.7)
 > 71 23 (7.7)
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be considered a primary differential diagnosis for adults 
suspected to have TB in this region of the Gambia. How-
ever, it must be remembered that sub-population varia-
tion in eating practices may alter the risk in children or 
in other parts of the Gambia. Further work is needed to 
identify the source of symptoms in smear negative TB 
suspects.
Limitations
  • Our results are not representative of the whole coun-
try although 80% of all TB cases in the country occur 
in the Greater Banjul area [19].
  • We did not study intermediate hosts (crustacea/shell-
fish) or their mammalian predators and thus our con-
clusions are limited to the importance of paragonimi-
asis as a differential diagnosis for TB in this study 
population, rather than for the generalised presence 
of paragonimus in other mammals and the potential 
for occasional human infections.
  • This study used archived samples in order to conduct 
a rapid assessment. Thus we were not able to directly 
ask participants about individual level eating habits. 
Blood was not available that would have allowed test-
ing for anti-paragonimus antibodies. Positive control 
DNA from adult worms was not available.
Additional file
Additional file 1: Table S1. Primer and probe sequences used in the 
study.
Fig. 1 Assay validation electrophoresis gels. a To estimate the assay’s 
limit of detection of pure DNA, PCR was performed on a dilution series 
of plasmid positive control (1000, 100, 10, 5.0, 1.0, 0.5 and 0.1 pg/µl). 
Amplification was seen in all dilutions for P. africanus and P. uterobilat-
eralis. Dilutions ranged from 1.0 ng/µl (dilution 1) to 0.1 pg/µl (dilution 
7). Samples were run on the same gel with P. africanus and P. utero-
bilateralis samples, and a no template control (“NTC”). b To estimate 
the assay’s limit of detection of DNA in sputum, PCR was performed 
using DNA extracted from sputum spiked with positive control DNA. 
12 sputum concentrates were spiked using the same dilution series 
as in (a). Samples were run on the same gel, with P. africanus and P. 
uterobilateralis samples, with plasmid positive control (“+ve cont”) and 
no template control (“NTC”). c Sensitivity of the PW-F/PAU-B primer set 
to the two West African target Paragonimus species was compared to 
P. westermani in a dilution series of pure plasmid positive control (1000, 
100, 10 and 5.0 pg/µl). d Specificity of PW-F/PAU-B (Series A) designed 
for P. africanus and P. uterobilateralis were compared to that of primers 
PW-F/PW-B (Series B) for P. westermani. DNA from known positive 
patient samples infected with related worm species to Paragonimus 
were tested, including, (1) Schistosoma mansoni, (2) Schistosoma hae-
matobium, (3) Necator americanus, (4) Opisthorchis spp. Amplification 
of a large sized product (800 base pairs) was seen for Opisthorchis spp. 
using the P. africanus/P. uterobilateralis primers. No unspecific amplifica-
tion was seen using primers PW-F/PW-B
◂
on the recommended zero patient design [15]. We used 
a prevalence of 1% as this is the criterion often used to 
define parasitic diseases of public health importance [17]. 
Our findings are in accordance with recent studies in 
Côte d’Ivoire, West Africa, which also found an absence 
of active cases of infection, amongst people attending an 
anti-tuberculosis centre, despite a 25% prevalence of anti-
Paragonimus antibodies  [11] and the presence of infec-
tive metacercariae in approximately 12% of local crabs 
collected  [18]. Overall, our study established that para-
gonimiasis, although possibly still present in our study 
population at a low prevalence, is not common enough to 
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